news 
As Tariffs Begin; What Will They Do To Drug Prices And Availability?
The Trump administration’s recent decision to impose tariffs on China, Mexico, and Canada has sparked concerns over the potential impact on drug prices and availability. The pharmaceutical industry is already grappling with complex global supply chains, and these tariffs may only exacerbate existing issues.
Firstly, it’s essential to acknowledge that 80% of drug ingredients are sourced from overseas, with China alone operating 13% of active pharmaceutical ingredient (API) manufacturing facilities for the US market. This reliance on international production is a significant challenge in maintaining the availability of medications at an affordable cost.
While the goal of returning pharmaceutical manufacturing to the US may be commendable, it’s crucial to recognize that generic and antibiotic drugs will be particularly vulnerable to these tariffs. With over 50% of consumed generics produced overseas, including life-saving treatments for cancer, antibiotics, and anticoagulants, any price increases or shortages can have disastrous consequences.
Experts predict that drug costs will rise by at least 10% in the short term due to existing contracts and inventory stockpiles. However, this increase is expected to have far-reaching and devastating effects on the healthcare system as companies struggle to absorb these additional costs.
The tariffs could also lead to a critical shortage of medications, particularly in hospitals and pharmacies where hoarding behavior may become prevalent. The risk of price gouging and reduced access to life-saving treatments for patients is real and concerning.
As drug distributors and manufacturers engage in stockpiling raw materials and APIs to mitigate supply chain disruptions, this can result in artificial scarcity, worsening existing shortages or creating new ones. This phenomenon will lead to reduced availability, increased demand, and subsequently, higher prices.
Furthermore, large-scale hoarding disrupts normal supply chain operations, making it challenging for manufacturers and distributors to accurately forecast and meet demand. The risk of medications expiring before they can be used is a significant concern, resulting in waste and financial losses.
It’s crucial that policymakers recognize the far-reaching consequences of these tariffs on drug prices and availability. Any resolution must prioritize accessibility and affordability while ensuring that patients are not disproportionately affected by these trade wars.
The long-term impact of neglecting our domestic pharmaceutical manufacturing capabilities will have severe consequences for vulnerable populations. It is critical that we address this issue promptly, focusing on the systemic problems within the global supply chain to ensure drug availability and accessibility.
In conclusion, as tariffs begin, it’s essential that we acknowledge the potential devastating effects on drug prices and availability. We must prioritize solutions that ensure patients’ access to life-saving treatments while also addressing the long-term consequences of our lack of self-sufficiency in critically needed drugs.
